January 6, 2022
Via: FierceBiotechNovartis is getting back into bed with Alnylam. More than a decade after severing its ties to the RNAi pioneer, Novartis has returned to the deal table for an ambitious early-stage collaboration to restore liver function in patients with end-stage […]
July 19, 2024
July 11, 2024
July 11, 2024